Диссертация (1141204), страница 20
Текст из файла (страница 20)
M. M., Perry D. M. et al. Treatment of staphylococcalsepticemia with vancomycin: report of thirty-three cases // New England Journalof Medicine. 1960. № 2 (262). C. 49–55.92. Kongkaew C., Noyce P.R., Ashcroft D.M. Hospital admissionsassociated with adverse drug reactions: a systematic review of prospectiveobservational studies // Annals of Pharmacotherapy. 2008. № 7–8 (42). C. 1017–1025.93.
Kullar R. et al. Validation of the effectiveness of a vancomycinnomogram in achieving target trough concentrations of 15--20 mg/L suggested bythe vancomycin consensus guidelines // Pharmacotherapy: The Journal of HumanPharmacology and Drug Therapy.
2011. № 5 (31). C. 441–448.94. Lacave G. et al. Incidence and risk factors of acute kidney injuryassociated with continuous intravenous high-dose vancomycin in critically illpatients: A retrospective cohort study // Medicine. 2017. № 7 (96).95. Lamb E.J., Tomson C.R. V, Roderick P.J. Estimating kidney functionin adults using formulae // Annals of clinical biochemistry. 2005. № 5 (42). C.321–345.96.
Lautenbach E. et al. Extended-spectrum $β$-lactamase-producingEscherichia coli and Klebsiella pneumoniae: risk factors for infection and impactof resistance on outcomes // Clinical Infectious Diseases. 2001. № 8 (32). C.1162–1171.97. Levey A.S. et al. Using standardized serum creatinine values in themodification of diet in renal disease study equation for estimating glomerularfiltration rate // Annals of Internal Medicine. 2006.
№ 4 (145). C. 247–254.98. Li C. et al. Clinical pharmacodynamics of meropenem in patients withlower respiratory tract infections // Antimicrobial Agents and Chemotherapy.2007.99. Li J. et al. Improving vancomycin prescription in critical illnessthrough a drug use evaluation process: a weight-based dosing intervention study// International journal of antimicrobial agents. 2012. № 1 (39). C. 69–72.100. Lipman J., Udy A.A., Roberts J.A. Do we understand the impact ofaltered physiology, consequent interventions and resultant clinical scenarios inthe intensive care unit? The antibiotic story // Anaesthesia and intensive care.2011. № 6 (39).
C. 999–1001.101. Liu C. et al. Clinical practice guidelines by the Infectious DiseasesSociety of America for the treatment of methicillin-resistant Staphylococcusaureus infections in adults and children // Clinical infectious diseases. 2011. № 3119(52). C. e18--e55.102. Lodise T.P. et al.Relationship between initial vancomycinconcentration-time profile and nephrotoxicity among hospitalized patients //Clinical infectious diseases. 2009. № 4 (49). C. 507–514.103.
Logman J. F. S. et al. Comparative effectiveness of antibiotics for thetreatment of MRSA complicated skin and soft tissue infections // Current medicalresearch and opinion. 2010. № 7 (26). C. 1565–1578.104. Makins R., Ballinger A. Gastrointestinal side effects of drugs // Expertopinion on drug safety. 2003. № 4 (2). C. 421–429.105. Mangano C.M. et al.Renal dysfunction after myocardialrevascularization: risk factors, adverse outcomes, and hospital resourceutilization. The Multicenter Study of Perioperative Ischemia Research Group.
//Annals of internal medicine. 1998. № 3 (128). C. 194–203.106. Mangin O. et al.Vancomycin pharmacokinetic andpharmacodynamic models for critically ill patients with post-sternotomymediastinitis // Clinical pharmacokinetics. 2014. № 9 (53). C. 849–861.107. Mar Fernández de Gatta Garcia M. del [и др.].Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients //Intensive Care Medicine.
2007. № 2 (33). C. 279–285.108. Martin J.H. et al. Pitfalls of using estimations of glomerular filtrationrate in an intensive care population // Internal Medicine Journal. 2011. № 7 (41).C. 537–543.109. Matzke G.R. et al. Pharmacokinetics of vancomycin in patients withvarious degrees of renal function. // Antimicrobial Agents and Chemotherapy.1984. № 4 (25). C. 433–437.110. McClaine R. J.
et al. Meta-analysis of trials evaluating parenteralantimicrobial therapy for skin and soft tissue infections // Clinical infectiousdiseases. 2010. № 8 (50). C. 1120–1126.111. Medve L., Gondos T. Epidemiology of postoperative acute kidneyinjury in hungarian intensive care units: An exploratory analysis // Renal Failure.2012. № 9 (34). C.
1074–1078.112. Michael C.A., Dominey-Howes D., Labbate M. The antimicrobialresistance crisis: causes, consequences, and management // Frontiers in publichealth. 2014. (2). C. 145.113. Moellering R.C., Krogstad D.J., Greenblatt D.J. Vancomycin therapyin patients with impaired renal function: a nomogram for dosage // Annals ofInternal Medicine. 1981. № 3 (94). C. 343–346.114. Moellering Jr R.C. Vancomycin: a 50-year reassessment // 2006.115. Mohammedi I. et al. Loading dose of vancomycin in critically illpatients: 15 mg/kg is a better choice than 500 mg // International journal ofantimicrobial agents.
2006. № 3 (27). C. 259–262.116. Moise-Broder P.A. et al. Pharmacodynamics of vancomycin andother antimicrobials in patients with Staphylococcus aureus lower respiratorytract infections // Clinical pharmacokinetics. 2004. № 13 (43). C. 925–942.120117. Moise-Broder P. A. et al. Pharmacodynamics of vancomycin andother antimicrobials in patients with Staphylococcus aureus lower respiratorytract infections // Clinical pharmacokinetics. 2004. № 13 (43).
C. 925–942.118. Murphy J. E., et al.Predictability of vancomycin troughconcentrations using seven approaches for estimating pharmacokineticparameters // American Journal of Health-System Pharmacy. 2006. № 23 (63). C.2365–2370.119. Neely M.N. et al. Are vancomycin trough concentrations adequate foroptimal dosing? // Antimicrobial agents and chemotherapy. 2014. № 1 (58). C.309–316.120.
NNIS S. National Nosocomial Infections Surveillance (NNIS) SystemReport, Data Summary from January 1990-May 1999, issued June 1999. A reportfrom the NNIS System. // American journal of infection control. 1999. № 6 (27).C. 520.121. Ocampos-Martinez E. et al. Determinants of early inadequatevancomycin concentrations during continuous infusion in septic patients //International journal of antimicrobial agents. 2012. № 4 (39). C.
332–337.122. of Health U.S.D., Services H., others Food and Drug AdministrationCenter for Drug Evaluation and Research (CDER) Guidance for Industry DrugInteraction Studies—Study Design, Data Analysis, Implications for Dosing, andLabeling Recommendations // Rockville, MD. 2012.123. Oostveen R.B. et al. Prevention of Infections in Cardiac Surgerystudy (PICS): study protocol for a pragmatic cluster-randomized factorialcrossover pilot trial // Trials.
2018. № 1 (19). C. 688.124. Otto G.P. et al. Renal outcome after vancomycin treatment and renalreplacement therapy in patients with severe sepsis and septic shock: aretrospective study // Journal of critical care. 2014. № 4 (29). C. 656–661.125. Owens Jr R.C., Ambrose P.G.
Antimicrobial safety: focus onfluoroquinolones // Clinical infectious diseases. 2005. № Supplement_2 (41). C.S144--S157.126. Paepe P. De, Belpaire F.M., Buylaert W.A. Pharmacokinetic andpharmacodynamic considerations when treating patients with sepsis and septicshock // Clinical Pharmacokinetics. 2002. № 14 (41). C. 1135–1151.127. Pai M.P. et al. Innovative approaches to optimizing the delivery ofvancomycin in individual patients // Advanced drug delivery reviews. 2014. (77).C.
50–57.128. Pai M.P., Cojutti P., Pea F. Pharmacokinetics and Pharmacodynamicsof Continuous Infusion Meropenem in Overweight, Obese, and Morbidly ObesePatients with Stable and Unstable Kidney Function: A Step Toward DoseOptimization for the Treatment of Severe Gram-Negative Bacterial Infectio //Clinical Pharmacokinetics. 2015.129. Pai M. P. et al. Aminoglycoside dosing in patients by kidney functionand area under the curve: the Sawchuk-Zaske dosing method revisited in the eraof obesity. // Diagnostic microbiology and infectious disease.
2014. № 2 (78). C.121178–187.130. Patel N. et al. Vancomycin: we can’t get there from here // Clinicalinfectious diseases. 2011. № 8 (52). C. 969–974.131. Pea F., Pavan F., Furlanut M. Clinical relevance of pharmacokineticsand pharmacodynamics in cardiac critical care patients // ClinicalPharmacokinetics. 2008. № 7 (47). C. 449–462.132. Pea F., Viale P. F.M. Antimicrobial therapy in critically ill patients //Clinical Pharmacokinetics. № 10 (44). C. 1009–1034.133. Pea F. et al. Prospectively validated dosing nomograms formaximizing the pharmacodynamics of vancomycin administered by continuousinfusion in critically ill patients // Antimicrobial agents and chemotherapy. 2009.№ 5 (53). C.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
